
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Chicago - Innovative therapeutic approaches may be needed to manage patients with localized psoriasis who despite having only limited areas of disease can present a major therapeutic challenge for dermatologists, said Steven R. Feldman, M.D., Ph.D.